UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Acute myeloid leukemia: 2019 update on risk‐stratification and management

American journal of hematology, 2018-10, Vol.93 (10), p.1267-1291

Estey, Elihu H.

2018

Volltextzugriff (PDF)

Acute myeloid leukemia: 2021 update on risk‐stratification and management

American journal of hematology, 2020-11, Vol.95 (11), p.1368-1398

Estey, Elihu H.

2020

Volltextzugriff (PDF)

Acute myeloid leukemia: 2013 update on risk‐stratification and management

American journal of hematology, 2013-04, Vol.88 (4), p.317-327

Estey, Elihu H.

2013

Volltextzugriff (PDF)

Acute myeloid leukemia: 2014 Update on risk‐stratification and management

American journal of hematology, 2014-11, Vol.89 (11), p.1063-1081

Estey, Elihu H.

2014

Volltextzugriff (PDF)

Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management

American journal of hematology, 2012-01, Vol.87 (1), p.89-99

Estey, Elihu H.

2012

Volltextzugriff (PDF)

Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet

Blood, 2019-04, Vol.133 (15), p.1630-1643

2019

Volltextzugriff (PDF)

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?

Journal of clinical oncology, 2016-02, Vol.34 (4), p.329-336

2016

Volltextzugriff (PDF)

A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia

Nature communications, 2018-01, Vol.9 (1), p.42-13, Article 42

2018

Volltextzugriff (PDF)

Acute myeloid leukemia stem cells and CD33-targeted immunotherapy

Blood, 2012-06, Vol.119 (26), p.6198-6208

2012

Volltextzugriff (PDF)

Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials

The lancet oncology, 2014-08, Vol.15 (9), p.986-996

2014

Volltextzugriff (PDF)

The past and future of CD33 as therapeutic target in acute myeloid leukemia

Blood reviews, 2014-07, Vol.28 (4), p.143-153

2014

Volltextzugriff (PDF)

Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment

Journal of clinical oncology, 2011-11, Vol.29 (33), p.4417-4423

2011

Volltextzugriff (PDF)

Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission

Blood, 2013-09, Vol.122 (10), p.1813-1821

2013

Volltextzugriff (PDF)

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

Blood, 2009-02, Vol.113 (9), p.1875-1891

2009

Volltextzugriff (PDF)

Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML

Blood, 2009-06, Vol.113 (24), p.6215-6224

2009

Volltextzugriff (PDF)

Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

Journal of clinical oncology, 2011-03, Vol.29 (9), p.1190-1197

2011

Volltextzugriff (PDF)

Improved outcomes with "7+3" induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data

Haematologica (Roma), 2023-01, Vol.108 (1), p.42-47

2023

Volltextzugriff (PDF)

Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome

Blood, 2007-10, Vol.110 (7), p.2302-2308

2007

Volltextzugriff (PDF)

Effect of Complete Remission and Responses Less Than Complete Remission on Survival in Acute Myeloid Leukemia: A Combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study

Journal of clinical oncology, 2010-04, Vol.28 (10), p.1766-1771

2010

Volltextzugriff (PDF)

Follow-up issues in survivors of hematologic malignancies – Current stance and future perspectives

Blood reviews, 2020-11, Vol.44, p.100674-100674, Article 100674

2020

Volltextzugriff (PDF)

Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia

Journal of hematology and oncology, 2020-10, Vol.13 (1), p.137-8, Article 137

2020

Volltextzugriff (PDF)

Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia

Haematologica (Roma), 2015-07, Vol.100 (7), p.927-934

2015

Volltextzugriff (PDF)

Significance of FAB subclassification of “acute myeloid leukemia, NOS” in the 2008 WHO classification: analysis of 5848 newly diagnosed patients

Blood, 2013-03, Vol.121 (13), p.2424-2431

2013

Volltextzugriff (PDF)

Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

Journal of clinical oncology, 2003-12, Vol.21 (24), p.4642-4649

2003

Volltextzugriff (PDF)

1 – 25 von 625

Suche als RSS-Feed

Aktive Filter

Nur zeigenGeprüft (Peer-Review)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Mit Volltextzugriff
(558)

Publikationsform

Artikel
(607)
Buchkapitel
(18)

Sprache

Englisch
(625)
Japanisch
(55)

Erscheinungsjahr

n.n

Thema

Science & Technology
(352)
Life Sciences & Biomedicine
(349)
Humans
(348)
Hematology
(221)
Middle Aged
(210)
Adult
(188)
Aged
(187)
Oncology
(187)
Medical Sciences
(180)
Biological And Medical Sciences
(179)
Female
(160)
Male
(157)
Leukemia, Myeloid, Acute - Drug Therapy
(112)
Hematologic And Hematopoietic Diseases
(104)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(103)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(103)
Prognosis
(100)
Treatment Outcome
(97)
Remission Induction
(90)
Acute Myeloid Leukemia
(86)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Acute myeloid leukemia: 2019 update on risk‐stratification and management

Acute myeloid leukemia: 2021 update on risk‐stratification and management

Acute myeloid leukemia: 2013 update on risk‐stratification and management

Acute myeloid leukemia: 2014 Update on risk‐stratification and management

Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management

Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?

A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia

Acute myeloid leukemia stem cells and CD33-targeted immunotherapy

Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials

The past and future of CD33 as therapeutic target in acute myeloid leukemia

Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment

Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML

Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

Improved outcomes with "7+3" induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data

Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome

Effect of Complete Remission and Responses Less Than Complete Remission on Survival in Acute Myeloid Leukemia: A Combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study

Follow-up issues in survivors of hematologic malignancies – Current stance and future perspectives

Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia

Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia

Significance of FAB subclassification of “acute myeloid leukemia, NOS” in the 2008 WHO classification: analysis of 5848 newly diagnosed patients

Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

Aktive Filter

Suchergebnisse filtern